A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Merck Sharp & Dohme LLC
Pfizer
Pfizer
Pfizer
Mirati Therapeutics Inc.
Amgen
Merck Sharp & Dohme LLC
Novartis
Eli Lilly and Company
US Oncology Research